New Search

Allan Eisemann, MD

Allan Eisemann, MD

  • Medical Director of Foley Cancer Center

Specialties:

Oncology/Hematology
View my videos

Call 802-747-1831

Accepting new patients.

  • Member of
    Rutland Regional Medical Team

Credentials

Profile

Gender:

Male

Areas of Interest

Hematology/Oncology

Service Line

Experience

Year began practicing: 1992

Year joined staff: 1999

Year began practicing in specialty: 1992

Medical School

1986, University of Kansas School of Medicine, Kansas City, Kansas, Medicine

Residency

1986-1989, University of Kansas School of Medicine, Internal Medicine

Fellowship

1989-1990, National Institutes of Health, Laboratory of Molecular and Cellular Biology 1990-1992, Georgetown University Hospital/Lombardi Cancer Center, Medical Oncology

Teaching or Professional Positions

Medical Director/Oncologist, Foley Cancer Center

Medical Director, Rutland Area Hospice, Vermont

Chairman, Cancer Program Committee

Chairman, Ethics Committee

Professional Memberships

American Society of Clinical Oncology

American Society of Hematology

American College of Physicians

American Medical Association

Vermont Medical Society

Honors, Awards, etc.

2003, Physician of the Year, Rutland Regional Medical Center

1991, American Cancer Society, Clinical Oncology Fellowship

1988, Resident of the Year, Internal Medicine, University of Kansas School of Medicine

Board Certifications

American Board of Internal Medicine; Internal Medicine 1989

American Board of Internal Medicine; Medical Oncology 1993

Related Documents

About Me

Publications:

Eisemann A, Becker NJ, Miner PB Jr., Fleming J.  Pancreatitis and gold treatment of rheumatoid arthritis. Ann Int Med 1989; 111:860-61

Eisemann A, Ahn JA, Graziani G, Tronick SR, Ron D.  Alternative splicing generates at least five different isoforms of the human basic-FGF receptor.  Oncogene 1991; 6:1195-1202

Clinical Protocols:

Rutland Regional Medical Center as Supplemental Investigator

  • A Phase III, randomized clinical trial of standard adjuvant endocrine therapy +/- chemotherapy in patients with 1-3 positive nodes, hormone receptor-positive and HER-2 negative breast cancer with recurrence score of 25 or less (SWOG S1007) 
  • A randomized Phase III trial of adjuvant therapy comparing chemotherapy alone to chemotherapy plus trastuzumab in women with node-positive or high risk node-negative HER2-low invasive breast cancer (NSABP B-47) 
  • A study of neratinib plus capecitabine versus lapatinib plus capecitabine in patients with HER-positive metastatic breast cancer who have received two or more HER-directed regimens in the metastatic setting (NALA Study, Puma Biotechnology) 
  • A Phase II prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate risk prostate cancer (RTOG 0815) 
  • A Phase III trial of short-term androgen deprivation with pelvic lymph noe or prostate bed only radiotherapy (SPPORT) in prostate cancer patients with a rising PSA after radical prostatectomy (RTOG 0534) 
  • A randomized phase III study of maintenance therapy with bevacizumab, pemetrexed or a combination of bevacizumab and pemetrexed following carboplatin, paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (ECOG E5508) 
  • A randomized phase III trial of lenalidomine vs. observation alone in patients with asymptomatic high-risk smoldering multiple myeloma (ECOG E3A06)

Locations

  • Foley Cancer Center

    Rutland Regional Medical Center 160 Allen Street Rutland, VT 05701

    Main: 802-747-1831
    Fax: 802-747-1826